We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 3,190

Changes to IP rights on the horizon: Canada introduces legislation to implement CETA
  • Gowling WLG
  • Canada
  • November 4 2016

We previously reported on important changes the recently signed Comprehensive Economic and Trade Agreement between Canada and the European Union


The SPC saga continues...
  • Dehns
  • European Union, United Kingdom
  • August 22 2014

The UK Intellectual Property Office (IPO) has asked for comments on this referral, but Respondents must be quick because the deadline is 29 August


Freedom to Utilize Genetic Resources? The Nagoya Protocol Two Years Later
  • Wilmer Cutler Pickering Hale and Dorr LLP
  • Global
  • October 12 2016

Two years ago today, the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits from their Utilization to the


FDA confirms its view on generic drug label carve-outs
  • McDermott Will & Emery
  • USA
  • August 21 2008

The Camptosar decision clarifies questions surrounding whether and to what extent a generic drug applicant must match each of the pioneer drug’s labeled uses or whether certain uses of the pioneer drug can be carved out by the generic applicant as a result of patent or statutory exclusivity bars


Intellectual property weekly abstracts bulletin week of August 18
  • Borden Ladner Gervais LLP
  • Canada
  • August 20 2014

In this case, Apotex sought to enter the market with its generic version of travoprost. The Court dismissed the proceeding on the basis that Apotex’


Managing IP risk in the age of personalized medicine
  • Foley & Lardner LLP
  • USA
  • August 6 2014

As discussed on Foley's Health Care Law Today blog, personalized medicine treatment trends and innovations are leading diagnostic and therapeutic


Marijuana Tipping Point: California and Florida Open Opportunities With Passage of New Laws
  • Akerman LLP
  • USA
  • November 9 2016

Yesterday's election will be viewed as a turning point in the emergence of new economies centered around marijuana. Ballot initiatives around the country resulted in important changes in eight states


Unlocking DNA Copyright Protection with Sequence Searches (Part 1)
  • GQ Life Sciences
  • USA
  • May 2 2016

If copyright protection becomes available for a significant number of engineered genetic sequences, copyright sequence searching could become just as


CRISPR: creation, commercialisation and conflict
  • Fraserburgh
  • USA
  • April 22 2015

In 1976 Herb Boyer, a University of California, San Francisco professor, and Robert Swanson, an unemployed venture capitalist, founded Genentech. The


Eversheds’ life sciences group 201415 - winter legal update
  • Eversheds Sutherland (International) LLP
  • Global
  • February 13 2015

The European Union has stated that cross-border innovation in science is being hindered by the current fragmented legal framework on the protection of